Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Natco Pharma Adcock Ingram Stake Drives Strategic Growth in African Markets
The Natco Pharma Adcock Ingram stake is rising from 35.75% to 49% after NATCO Pharma Limited's board approved a combined investment of up to ₹1,400 crores in its South African operations. The move pairs capital infusion into its wholly owned subsidiary with the acquisition of additional shares in...
Global Instability Impacting Generic Pharmaceutical Sustainability in Portugal
Global instability impacting generic pharmaceutical sustainability has become a pressing challenge for Portugal, where rising international conflicts are undermining the economic viability of generic drug production. After 34 years of ensuring affordable access to essential treatments, these medi...
BFI Healthcare Procurement South Africa Driving Infrastructure Advancements
South Africa’s healthcare system stands at a pivotal moment as BFI healthcare procurement accelerates the delivery of modern hospitals and clinics. The Department of Health is preparing 11 formal bids for the Budget Facility for Infrastructure (BFI), signalling a decisive shift from slow annual a...